AIM： To determine the effects of the calcineurin inhibitors, cyclosporine and tacrolimus, on hepatitis C virus （HCV） replication and activity of recurrent hepatitis C in patients post liver transplantation. METHODS...AIM： To determine the effects of the calcineurin inhibitors, cyclosporine and tacrolimus, on hepatitis C virus （HCV） replication and activity of recurrent hepatitis C in patients post liver transplantation. METHODS： The data of a cohort of 107 patients who received liver transplantation for HCV-associated liver cirrhosis between 1999 and 2003 in our center were retrospectively analyzed. The level of serum HCV-RNA and the activity of recurrent hepatitis were compared between 47 patients who received either cyclosporine or tacrolimus as the primary immunosuppressive agent and an otherwise similar immunosuppressive regimen which did not lead to biliary complications within the first 12 mo after transplantation. RESULTS： HCV-RNA increased within 3 mo after transplantation but the differences between the cyclosporine group and the tacrolimus group were insignificant （P=0.49 at 12 too）. In addition, recurrent hepatitis as determined by serum transarninases and histological grading of portal inflammation and fibrosis showed no significant difference after 12 mo （P= 0.34）.CONCLUSION： Cyclosporine or tacrolimus as a primary immunosuppressive agent does not influence the induction or severity of recurrent hepatitis in HCV- infected patients after liver transplantation.展开更多
原发性肝癌（primary carcinoma of the liver,PLC）是指由肝细胞、肝内胆管上皮细胞或两者混和发生的恶性肿瘤。流行病学研究证实,肝癌已跃居世界恶性肿瘤致死病因第2位,中国每年约有38.3万人死于肝癌,约占世界的51%,病死率也跃居我国...原发性肝癌（primary carcinoma of the liver,PLC）是指由肝细胞、肝内胆管上皮细胞或两者混和发生的恶性肿瘤。流行病学研究证实,肝癌已跃居世界恶性肿瘤致死病因第2位,中国每年约有38.3万人死于肝癌,约占世界的51%,病死率也跃居我国恶性肿瘤致死原因第2位-（[2]）。PLC的治疗方法日新月异,尤其是非手术治疗方法得到进一步认可,生物疗法及综合治疗的理念越来受到青睐。展开更多
文摘AIM： To determine the effects of the calcineurin inhibitors, cyclosporine and tacrolimus, on hepatitis C virus （HCV） replication and activity of recurrent hepatitis C in patients post liver transplantation. METHODS： The data of a cohort of 107 patients who received liver transplantation for HCV-associated liver cirrhosis between 1999 and 2003 in our center were retrospectively analyzed. The level of serum HCV-RNA and the activity of recurrent hepatitis were compared between 47 patients who received either cyclosporine or tacrolimus as the primary immunosuppressive agent and an otherwise similar immunosuppressive regimen which did not lead to biliary complications within the first 12 mo after transplantation. RESULTS： HCV-RNA increased within 3 mo after transplantation but the differences between the cyclosporine group and the tacrolimus group were insignificant （P=0.49 at 12 too）. In addition, recurrent hepatitis as determined by serum transarninases and histological grading of portal inflammation and fibrosis showed no significant difference after 12 mo （P= 0.34）.CONCLUSION： Cyclosporine or tacrolimus as a primary immunosuppressive agent does not influence the induction or severity of recurrent hepatitis in HCV- infected patients after liver transplantation.
文摘原发性肝癌（primary carcinoma of the liver,PLC）是指由肝细胞、肝内胆管上皮细胞或两者混和发生的恶性肿瘤。流行病学研究证实,肝癌已跃居世界恶性肿瘤致死病因第2位,中国每年约有38.3万人死于肝癌,约占世界的51%,病死率也跃居我国恶性肿瘤致死原因第2位-（[2]）。PLC的治疗方法日新月异,尤其是非手术治疗方法得到进一步认可,生物疗法及综合治疗的理念越来受到青睐。
